CALL US:022-2204 0015 / 16 / 17   isa@saffronmedia.in
HOME NEWS INGREDIENT MART EVENTS TOPICS INTERVIEW EDIT
 
News
 
Yash Ved, Mumbai September 19 , 2020
BDR Pharma is planning to invest in backward integration to create huge key starting materials (KSM) and active pharmaceutical ingredient (API) facilities to be self-reliant and will launch products in therapy areas like prostate/breast/thyroid cancer, critical care, cardiology, neurology, dermatology and gynaecology.

The company stated that it will continue to work on complex molecules to create accessibility and affordability of products across the globe to curb various life threatening diseases.

Dharmesh Shah, chairman and managing director, BDR Pharma said, “We at BDR Pharma have scaled up the process of research and manufacturing facilities to support the eradication of the virus. Our research, development, and expansions are self-funded until date. We are glad to proclaim that with the accompaniment of growth alongside, we continue to be a debt-free company. We are also planning to invest in seeking access to state of the art infrastructure with international standards to create large capacities of products to export globally with no constraints.”

The company is also planning to raise funds for new segments of monoclonal antibodies and biosimilars in the future years.

Shah further added that in the race to curb the complications caused by the COVID-19, our workforce is working extensively to expedite the discovery of the drug. We first introduced remedesvir followed by favipiravir in the early stages to control the outbreak. They showed positive results while prescribed to patients with moderate symptoms. Our team is now working on another product about which we are optimistic, to help reduce the burden. We are also assured with the availability of sufficient stock of raw materials like hydroxycholoroquin, osalatamavir, lopinavir and ritonavir for medicines and formulations to meet requirements for India and our export facilities."

BDR is recognized as a niche player in manufacturing of pharmaceutical APIs and for the renowned new age formulations. BDR Group of companies has grown steadily in the pharmaceutical industry over the last 15 years, in both domestic and international arenas. BDR Group focuses on development in 6 specialized therapeutic segments, such as oncology, critical care, gynaecology and neurology, dermatology and women’s health which are its dream segment.

The company's mission is to become strategic innovator and enhance healthcare by endowing the society with innovative products and medicines at affordable prices in life saving category.

Share This Story

Leave a Reply
Your name (required)   Your email (required)
         
Website (required)
   
CommenT
 
Enter Code (Required)

 

 

 
INGREDIENT MART

RECENT NEWS

TOPICS
The healthy snacks segment is estimated to be around 2 per cent of the overall snacks market in India, according to expe ...

 

MAIN LINKS OUR SERVICES OTHER PRODUCTS ONLINE MEDIA  
 
About Us
Contact Us
News Archives
 

Product Finder
Features and Articles
News
 
Chronicle Pharmabiz
Food & Bevergae News
Ingredients South Asia
 
Media Information
Rate Card
Advertise
 
 
Copyright © 2013 Saffron Media Pvt Ltd. All Rights Reserved.
Best View in Internet Explorer(9.0) or Firefox(26.0)